| pubmed-article:2532923 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2532923 | lifeskim:mentions | umls-concept:C0023895 | lld:lifeskim |
| pubmed-article:2532923 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:2532923 | lifeskim:mentions | umls-concept:C0078595 | lld:lifeskim |
| pubmed-article:2532923 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:2532923 | pubmed:dateCreated | 1990-3-6 | lld:pubmed |
| pubmed-article:2532923 | pubmed:abstractText | The pharmacokinetics of xamoterol, a beta 1-adrenoceptor partial agonist, have been studied in patients with liver disease and a group of age- and sex-matched normal controls. No significant differences were observed after the oral administration of xamoterol 200 mg. The low bioavailability of xamoterol was confirmed (6.1% in patients, 6.9% in controls). After i.v. xamoterol 0.2 mg kg-1, no significant differences between the groups were observed. A small increase in the terminal plasma elimination half-life (t1/2) was observed in patients when compared with controls (15.3 +/- 6.4 vs 8.4 +/- 2.8 h, mean +/- s.d., P = 0.08). Renal clearance accounted for about 50% of total clearance in patients and about 30% in controls. It is suggested that in patients with heart failure, hepatic dysfunction would probably not influence xamoterol disposition. | lld:pubmed |
| pubmed-article:2532923 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2532923 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2532923 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2532923 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2532923 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2532923 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2532923 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2532923 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2532923 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2532923 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2532923 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2532923 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2532923 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2532923 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2532923 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2532923 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2532923 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:2532923 | pubmed:issn | 0306-5251 | lld:pubmed |
| pubmed-article:2532923 | pubmed:author | pubmed-author:ShanksR GRG | lld:pubmed |
| pubmed-article:2532923 | pubmed:author | pubmed-author:NichollsD PDP | lld:pubmed |
| pubmed-article:2532923 | pubmed:author | pubmed-author:TaggartA JAJ | lld:pubmed |
| pubmed-article:2532923 | pubmed:author | pubmed-author:BastainWW | lld:pubmed |
| pubmed-article:2532923 | pubmed:author | pubmed-author:McCannJ PJP | lld:pubmed |
| pubmed-article:2532923 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2532923 | pubmed:volume | 28 | lld:pubmed |
| pubmed-article:2532923 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2532923 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2532923 | pubmed:pagination | 718-21 | lld:pubmed |
| pubmed-article:2532923 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:2532923 | pubmed:meshHeading | pubmed-meshheading:2532923-... | lld:pubmed |
| pubmed-article:2532923 | pubmed:meshHeading | pubmed-meshheading:2532923-... | lld:pubmed |
| pubmed-article:2532923 | pubmed:meshHeading | pubmed-meshheading:2532923-... | lld:pubmed |
| pubmed-article:2532923 | pubmed:meshHeading | pubmed-meshheading:2532923-... | lld:pubmed |
| pubmed-article:2532923 | pubmed:meshHeading | pubmed-meshheading:2532923-... | lld:pubmed |
| pubmed-article:2532923 | pubmed:meshHeading | pubmed-meshheading:2532923-... | lld:pubmed |
| pubmed-article:2532923 | pubmed:meshHeading | pubmed-meshheading:2532923-... | lld:pubmed |
| pubmed-article:2532923 | pubmed:meshHeading | pubmed-meshheading:2532923-... | lld:pubmed |
| pubmed-article:2532923 | pubmed:meshHeading | pubmed-meshheading:2532923-... | lld:pubmed |
| pubmed-article:2532923 | pubmed:meshHeading | pubmed-meshheading:2532923-... | lld:pubmed |
| pubmed-article:2532923 | pubmed:meshHeading | pubmed-meshheading:2532923-... | lld:pubmed |
| pubmed-article:2532923 | pubmed:meshHeading | pubmed-meshheading:2532923-... | lld:pubmed |
| pubmed-article:2532923 | pubmed:meshHeading | pubmed-meshheading:2532923-... | lld:pubmed |
| pubmed-article:2532923 | pubmed:meshHeading | pubmed-meshheading:2532923-... | lld:pubmed |
| pubmed-article:2532923 | pubmed:meshHeading | pubmed-meshheading:2532923-... | lld:pubmed |
| pubmed-article:2532923 | pubmed:meshHeading | pubmed-meshheading:2532923-... | lld:pubmed |
| pubmed-article:2532923 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2532923 | pubmed:articleTitle | The pharmacokinetics of xamoterol in liver disease. | lld:pubmed |
| pubmed-article:2532923 | pubmed:affiliation | Royal Victoria Hospital, Belfast, Northern Ireland. | lld:pubmed |
| pubmed-article:2532923 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2532923 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
